Procalcitonin May Help Distinguish Between Infections and Flare in AAV
Rituximab May Be More Effective Than Azathioprine for AAV Relapse Prevention
EULAR Recommendations for AAV Management Updated
Study Identifies Prognostic Factors in ANCA-Associated Vasculitis
Neutrophils and Neutrophil Extracellular Traps May Contribute to AAV Pathogenesis
Fatigue in AAV May Meet Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
A Case of AAV With Gastrointestinal System Involvement
Higher Mortality and Infection Rates Seen in Patients With AAV and ESKD
CanVasc Publishes Updated Recommendations for Avacopan Use in AAV
Latest Clinical Trials
Features & Insights
Understanding the Relationship Between AAV and Cardiovascular Disease
Studies indicate that patients with ANCA-associated vasculitis have a heightened risk of developing cardiovascular disease.
At 40, Orphan Drug Act Enjoys Rare Bipartisan Support
Rare disease advocates are marking the 40th anniversary of the landmark Orphan Drug Act, which has led to over 1100 approvals for new therapies.
Drug Repurposing: A Novel Strategy for a Deeply Unequal World
The belief driving drug repurposing is that the current drugs that we do have may yet possess therapeutic aspects we aren’t fully aware of.
Exploring the Parental Burden of Care of Children With Rare Diseases
The parental burden of care of children with rare diseases is considerable and deserves due attention and support.
EveryLife Foundation Navigates Complex Issues to Advocate for Rare Disease Patients
The EveryLife Foundation for Rare Diseases pushes a legislative agenda aimed at benefitting the 30 million Americans with a rare disease.
Synthetic Control Arms Could Facilitate More RCTs in Rare Disease
Dr. Rahul Banerjee of the University of Washington discusses the benefits and drawbacks of using synthetic control arms in randomized controlled trials.